Yumanity Therapeutics (YMTX) Stock Price, News & Analysis

Company Overview

Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. The company focuses on discovering disease-modifying therapies to treat neurodegenerative diseases, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, and frontotemporal lobar degeneration. Its lead program is YTX-7739, a novel small molecule that is in Phase I clinical trial for the treatment of Parkinson's disease and related disorders of a-synuclein. The company is also developing YTX-9184, which is in preclinical studies to treat neurological disorders. Yumanity Therapeutics Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.56 to $1.89
• 52-Week Range: N/A
• Volume: 6,790 shs
• Average Volume: 473,083 shs
• Market Capitalization: $7.46 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

YMTX Stock Analysis - Frequently Asked Questions

How were Yumanity Therapeutics' earnings last quarter?

Yumanity Therapeutics, Inc. (NASDAQ:YMTX) announced its earnings results on Thursday, August, 12th. The company reported ($1.03) earnings per share for the quarter, missing the consensus estimate of ($0.84) by $0.19. The company earned $2.11 million during the quarter, compared to analysts' expectations of $2.27 million. Yumanity Therapeutics had a negative net margin of 660.61% and a negative trailing twelve-month return on equity of 263.34%.

What other stocks do shareholders of Yumanity Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Yumanity Therapeutics investors own include NIO (NIO), Arch Therapeutics (ARTH), Aytu BioPharma (AYTU), Clarus Therapeutics (CRXTQ), Ford Motor (F), Novavax (NVAX) and Sorrento Therapeutics (SRNE).

Company Calendar

• Last Earnings: 8/12/2021
• Today: 5/28/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:YMTX
• CIK: 1445283
• Web: www.yumanity.com
• Phone: (617) 409-5300
• Fax: N/A
• Employees: 40
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($3.00)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$39.50 million
• Net Margins: -660.61%
• Pretax Margin: -660.61%
• Return on Equity: -263.34%
• Return on Assets: -107.08%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.21
• Quick Ratio: 2.21

Sales & Book Value

• Annual Sales: $4.84 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.28 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 10,856,000
• Free Float: 9,504,000
• Market Cap: $7.46 million
• Optionable: Not Optionable
• Beta: 0.32